ALDER BIOPHARMACEUTICALS INC 4
4 · ALDER BIOPHARMACEUTICALS INC · Filed Feb 13, 2017
Insider Transaction Report
Form 4
Schatzman Randall C
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2017-02-09$1.65/sh+30,000$49,500→ 145,172 total - Sale
Common Stock
2017-02-09$25.03/sh−30,000$750,756→ 115,172 total - Exercise/Conversion
Stock Option (Right to Buy)
2017-02-09−30,000→ 78,181 totalExercise: $1.65Exp: 2018-07-22→ Common Stock (30,000 underlying)
Footnotes (4)
- [F1]The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2016.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2016.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4.
- [F4]The shares subject to this stock option are fully vested.